Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, data from China on high-dose mazdutide, and more.<br><br>Related Content:<br>A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026

New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions

JAMA Medical News

From the JAMA Network, this is the JAMA Medical News Podcast. Discussing timely topics in clinical medicine, biomedical sciences, public health, and health policy, featured in the Medical News section of JAMA. Today we're bringing you clinical updates from the American Diabetes Association's annual scientific sessions, which recently wrapped up in New Orleans. I'm Jennifer Abasi for JAMA Medical News. My guest today is Dr. Rita Kalyani.

Dr. Kalyani is the ADA's Chief Scientific and Medical Officer and a Professor of Medicine at Johns Hopkins University School of Medicine. Dr. Kalyani, thank you for joining us. Thanks for having me. So you're going to share with us some of the important research on diabetes and obesity care from the conference. This year's program was packed with new research on incretin-based therapies. So let's start there.

I have to say I had a really hard time narrowing down the studies we're going to talk about because there are so many interesting things happening in this space. I thought we'd begin with ritatratide. This is an investigational triple agonist, so three hormones in one injection. It's a glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, and a glucagon receptor agonist.

So data from two phase 3 studies were presented at the meeting, one in people with type 2 diabetes and the other in people with obesity. What did we learn about this novel drug? We learned a lot about this novel drug. And as you mentioned, it is a triple hormone receptor agonist and really an exciting novel mechanism of lowering blood glucose and treating diabetes.

New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions

Read the full transcript

The candid version is on a podcast,
not the earnings call.

New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.